- Revance’s long-acting neuromodulator RT002, along with its unique
proprietary peptide and formulation technology, will be featured in 11
podium and poster presentations at the TOXINS 2019 conference in
"We will have a significant presence at the bi-annual TOXINS 2019, which
attracts scientific and clinical experts from around the world who are
specifically focused on the basic science and clinical applications of
neurotoxins," said
Revance’s scheduled presentations are:
Podium Presentations
- Pooled Results from Two Phase 3 Pivotal Studies of
DaxibotulinumtoxinA for the Treatment of Glabellar Lines (
Jan. 17 ,4:30 pm CET ,Clinical Workshop 1B). Presenter: Dr.Steven G. Yoelin , Ophthalmologist atSteve Yoelin MD Medical Associates .
- Outcomes of Week-24 Completers and Subjects who had Follow-Up
Beyond Week 24 after a Single Treatment of DaxibotulinumtoxinA;
Results of a Phase 2 Open-Label Dose-Escalating Study in Isolated
Cervical Dystonia (
Jan. 18 ,3:30 pm CET ,Clinical Workshop 3A). Presenter: Dr.Atul Patel ,Kansas City Bone & Joint Clinic .
Poster Presentations (
Aesthetics
- Pooled Results from Two Phase 3 Pivotal Studies of DaxibotulinumtoxinA for the Treatment of Glabellar Lines
- Results of a Large Open-Label Safety Study of DaxibotulinumtoxinA in Glabellar Lines
- A Head-to-Head Dose-Ranging Study of DaxibotulinumtoxinA in the Treatment of Glabellar Lines: Results of the BELMONT Study
Therapeutics
- Immunogenicity of DaxibotulinumtoxinA in Adults with Cervical Dystonia from a Phase 2 Dose-Escalation Multicenter Study
- Outcomes of Week-24 Completers and Subjects who had Follow-Up Beyond Week 24 after a Single Treatment of DaxibotulinumtoxinA: Results of a Phase 2 Open-Label, Dose-Escalating Study in Isolated Cervical Dystonia
- Methodology of a Phase 2 Randomized, Double-Blind, Placebo-Controlled, Parallel group, Dose-Ranging 36-week Multicenter Trial to Evaluate the Efficacy and Safety of DaxibotulinumtoxinA for the Treatment of Upper Limb Spasticity in Adults after Stroke or Traumatic Brain Injury
Non-Clinical
- Revance's Novel Peptide Excipient (RTP004) and its Role in Stabilizing DaxibotulinumtoxinA against Aggregation
- Development of Cell-Based Potency Assay for Release and Stability Testing of Drug Substance and Drug Product
- Non-Clinical Overview of DaxibotulinumtoxinA to Support Registration for Human Use
- Novel Peptide Excipient RTP004 Enhances the Binding of Botulinum Neurotoxin, a Cell Binding Domain HC to Rat Brain Synaptosomes
- Stabilizing Effect of RTP004 on Non-Specific Surface Adsorption in Drug Product Manufacturing of DaxibotulinumtoxinA
About
“Revance Therapeutics” and the Revance logo are registered trademarks of
Forward-Looking Statements
This press release contains forward-looking statements, including
statements related to
Forward-looking statements are subject to risks and uncertainties
that could cause actual results to differ materially from our
expectations. These risks and uncertainties include, but are not limited
to: the outcome, cost, and timing of our product development activities
and clinical trials; the uncertain clinical development process,
including the risk that clinical trials may not have an effective design
or generate positive results; our ability to obtain and maintain
regulatory approval of our drug product candidates; our ability to
obtain funding for our operations; our plans to research, develop, and
commercialize our drug product candidates; our ability to achieve market
acceptance of our drug product candidates; unanticipated costs or delays
in research, development, and commercialization efforts; the
applicability of clinical study results to actual outcomes; the size and
growth potential of the markets for our drug product candidates; our
ability to successfully commercialize our drug product candidates and
the timing of commercialization activities; the rate and degree of
market acceptance of our drug product candidates; our ability to develop
sales and marketing capabilities; the accuracy of our estimates
regarding expenses, future revenues, capital requirements and needs for
financing; our ability to continue obtaining and maintaining
intellectual property protection for our drug product candidates; and
other risks. Detailed information regarding factors that may cause
actual results to differ materially from the results expressed or
implied by statements in this press release may be found in Revance's
periodic filings with the Securities and Exchange Commission (the
"SEC"), including factors described in the section entitled "Risk
Factors" of our quarterly report on Form 10-Q filed
View source version on businesswire.com: https://www.businesswire.com/news/home/20190115005234/en/
Source:
INVESTORS
Revance Therapeutics, Inc.:
Jeanie Herbert
(714)
325-3584
jherbert@revance.com
or
Burns
McClellan, Inc.:
John Grimaldi
(212) 213-0006
jgrimaldi@burnsmc.com
or
MEDIA
General
Media:
TOGORUN:
Mariann Caprino
(917) 242-1087
m.caprino@togorun.com
or
Trade
Media:
Nadine Tosk
(504) 453-8344
nadinepr@gmail.com